Characteristics of clinical trials associated with appeal and return on investment to participants: a review and framework
Open Access
- 27 September 2025
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (10)
Abstract
Despite decades of investment in clinical research infrastructure, patient participation in clinical trials remains strikingly low. In the United States, fewer than 1 in 10 adults report ever being invited to participate in a clinical trial, and among those, less than half ultimately enroll. In oncology, across all adult cancer patients, only about 8% enroll in a clinical trial, regardless of eligibility or trial availability. Active engagement of their patients in cancer clinical trials substantially enhances scientific knowledge, and patient participation is required to obtain approval for novel therapeutics. Analyses focusing on evaluating whether clinical trial participation improves survival for participants have yielded conflicting results. Yet, there is limited data or metrics to assess the specific attributes of oncology trials that hold greater appeal or return on investment to participants, limiting researchers’ ability to determine if these factors vary across different populations. Our group demonstrated that patients with limited English proficiency were unlikely to participate in studies not sponsored by industry as compared to industry-sponsored studies. If trial participation for specific populations can differ by sponsor type, it could also differ by the trial’s appeal or return on investment. While the underrepresentation of racial and ethnic minority groups in trials is attributed to multiple factors, it is possible that patients from these groups are less likely to be offered participation in studies with higher appeal or return on investment, due to systemic biases, disparities in recruitment practices, and/or lack of access. In this manuscript, we propose a systematic framework for evaluating attributes of interventional oncology clinical trials, with an emphasis on the study’s purpose, experimental design, and investigational agent. This framework aims to pinpoint characteristics that may enhance trials’ appeal or return on investment to participants and could lay a foundation for future research. This will allow investigators to assess the return on investment of appeal of studies offered across different patient populations.Keywords
This publication has 68 references indexed in Scilit:
- Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic reviewCancer, 2007
- Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factorsThe Lancet Oncology, 2006
- Sample size and the ethics of non-inferiority trialsThe Lancet, 2005
- Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured reviewThe Lancet, 2004
- Randomized, Controlled Trial of an Easy-to-Read Informed Consent Statement for Clinical Trial Participation: A Study of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2003
- Attitudes towards clinical research amongst participants and nonparticipantsJournal of Internal Medicine, 2002
- Randomized Clinical Trials in Oncology: Understanding and Attitudes Predict Willingness to ParticipateJournal of Clinical Oncology, 2001
- Reasons for accepting or declining to participate in randomized clinical trials for cancer therapyBritish Journal of Cancer, 2000
- Patients' willingness to enter clinical trials: Measuring the association with perceived benefit and preference for decision participationSocial Science & Medicine, 1991
- Dose-finding studies in clinical drug developmentEuropean Journal of Clinical Pharmacology, 1988